Back to Top Skip to main content

DTRA contributes to historic Ebola vaccine effort

Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz) Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz)

Recommended Content:

Immunization Healthcare | Immunizations | Global Emerging Infections Surveillance | Global Health Engagement | Global Health Engagement

FORT BELVOIR, Va. — The team of researchers and program managers at the Defense Threat Reduction Agency (DTRA) that has worked to counter the threat of the Ebola Virus Disease (EVD) welcomed the announcement of the U.S. Food and Drug Administration’s (FDA) approval of the vaccine, Ervebo ®, to the pharmaceutical company Merck & Co., Inc., December 19, 2019.

The approval of the vaccine represents the culmination of nearly two decades of efforts by a host of teams from across the public and private sectors such as DTRA and Merck, international partners in North America, Europe and Africa, and non-governmental and international organizations. The World Health Organization (WHO) describes EVD as a rare but severe hemorrhagic fever. EVD has killed thousands over the course of outbreaks, primarily in sub-Saharan Africa, since it first appeared in the 1970s.

DTRA, a Department of Defense combat support agency that identifies and combats biological threats as part of its mission to counter weapons of mass destruction (WMD), began its work on the vaccine in 2014 during an especially deadly outbreak in West Africa. The outbreak made clear the danger EVD posed to U.S. national security interests abroad, as well as to the U.S. domestic population in the event of a pandemic. To counter the threat, DTRA quickly initiated a strategy to get a vaccine approved. The combat support agency coordinated a series of investment efforts and partnerships to deliver a baseline platform for a viable vaccine candidate to mitigate the spread of the deadly disease.

“DTRA’s agile contracting, and well-placed contacts throughout government, academia, and industry allowed DTRA to form partnerships and guide development of this vaccine from the early stages of development, through crucial preclinical, and critical phase 1 clinical safety trials to the actual phase 2 clinical efficacy trial that demonstrated effectiveness of this vaccine during the outbreak,” said L. Revell Phillips Ph.D., a member of DTRA’s research and development team.

DTRA’s pioneering approach started with a contract to BioProtection Systems, a small biotech company. DTRA and BioProtection Systems partnered with Public Health Agency Canada, who began developing the vaccine in 2001, to accelerate its development. With these three teams working together, the vaccine progressed to a series of nonclinical and clinical studies conducted at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) and Walter Reed Army Institute of Research (WRAIR) defense laboratories.

As the effort evolved, DTRA leveraged its USAMRIID partner’s research capacity, resulting in international partnering agreements with the WHO. DTRA also coordinated with teams across the U.S. government as development of the vaccine progressed. The efforts of this research and development consortium produced viable data that would be transitioned to next-level partners.

“We exercised our ability to develop partnerships for a relevant need, which was critical in transitioning medical countermeasures to our advanced developers at the speed of relevancy,” said Army Maj. Jeffrey Froude, DTRA’s program manager for the EVD Vaccine.

Froude explained that DTRA bolstered its research and development investments through two key U.S. governmental partners. First, DTRA worked closely with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for advanced trials and manufacturing activities. Second, DTRA teamed with the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the task of immunoassay development. For that development effort, JPEO-CBRND’s, office of the Joint Program Manager for CBRN Medical took the lead.

Following several years of coordinated research and development efforts by the coalition of partners, the promising vaccine candidate transitioned to next-level partners BARDA and Merck for more advanced human clinical trials and product manufacturing of the EVD vaccine.

“This vaccine’s rapid progress is a testament to the power of partnerships among government agencies and with the private sector,” said BARDA director Rick Bright.

Next-level partner BARDA and Merck, served as the transition point to conduct more advanced human clinical trials and product manufacturing on the Ebola vaccine with the Joint Program Executive office (JPEO) providing a testing capability that allowed Merck to test human and non-human primate samples. The Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM-CBRN), Army Col. Ryan Eckmeier, stated that this “interagency partnership from the beginning was critical to advancing this vaccine product.”

Merck’s expertise with licensing and manufacturing was instrumental in advancing the vaccine. The pharmaceutical giant partnered with the WHO, United Nations International Children's Emergency Fund, and Gavi Vaccine Alliance, among others, to strategize on how to best implement future public health preparedness and response efforts against EVD.

“We share in this achievement, and thank you all personally for your amazing support over the last five years,” said Beth-Ann G. Coller, executive director of Merck’s vaccine team in a note to the DTRA team. “This has truly been a journey and one that we are proud to have shared with our colleagues in DoD. Without the early and continued support of DTRA we would not be here today.”

DTRA continues to leverage its successful partnerships as the agency works to develop future countermeasures. DTRA and BARDA have active partnering agreements to develop vaccine and therapeutic medical countermeasures to address a diverse range of viral and bacterial infectious disease threats. Efforts will use a similar model to the one that supported development and approval of the EVD vaccine.

“As DTRA moves forward to new challenges, we will leverage continued utilization of the Ebola vaccine model, using a diverse range of ways that we can work with our academic, international, interagency and industrial partners through grants, contracts and other transaction authorities,” said Froude. “We have a proven paradigm on how to efficiently advance medical countermeasures working with our U.S. government partners in these endeavors.”

Disclaimer: Re-published content may be edited for length and clarity. Read original post.

You also may be interested in...

Air Force International Health Specialists bring experience to pandemic response

Article
6/12/2020
Two men in masks...one in military uniform, the other casually dressed

Stepping out of your comfort zone and being part of the larger DOD mission is crucial to grow as a military medic.

Recommended Content:

Coronavirus | Global Health Engagement | Global Health Engagement

DoD Establishes Collaborative Virus Genetic Sequencing Capability for COVID-19

Article
6/5/2020
Image of two scientists in masks looking at a computer monitor

COVID-19 sequencing process will provide military commanders and other DoD leadership with critical information to guide force health protection decision-making.

Recommended Content:

Armed Forces Health Surveillance Branch | Coronavirus | Global Emerging Infections Surveillance

Genetic sequence data for SARS-CoV-2

Infographic
6/5/2020
Infographic describing how DoD was able to conduct genome sequencing on the COVID-19 virus

Genetic sequence data for SARS-CoV-2, the virus that causes #COVID19, plays a vital role in force health protection efforts within the DoD. To jumpstart sequencing efforts, the Armed Forces Health Surveillance Branch's Global Emerging Infections Surveillance and Response applied a collaborative approach to sequencing capabilities. Resulting sequence data will provide critical information about transmission patterns, track diagnostic effectiveness, and guide the development and evaluation of medical countermeasures.

Recommended Content:

Armed Forces Health Surveillance Branch | Coronavirus | Global Emerging Infections Surveillance

WRNMMC Operates Drive-Up Immunization Clinic

Article
6/3/2020
Nurse giving a shot to a girl; both wearing masks

Parents and others (are encouraged) to maintain their immunization health during COVID-19.

Recommended Content:

Coronavirus | Immunization Healthcare

Recommendations for Mass Immunization Events During Pandemic Conditions

Fact Sheet
5/27/2020

During pandemic conditions, planners of mass immunization events need to consider additional measures to minimize risk of COVID-19 or similar infectious disease transmission.

Recommended Content:

Immunization Healthcare

Foreign liaison officers bring new perspective to MHS

Article
5/26/2020
Image of three men talking to each other

Medical information exchange aids in better care everywhere

Recommended Content:

Global Health Engagement | Coronavirus | Global Health Engagement

BAMC infectious disease doc aids Guam's COVID response

Article
5/14/2020
Image of soldier standing, surrounded by tropical water

The Navy has since undertaken an aggressive mitigation plan of isolating, quarantining, and treating affected Sailors to keep the ship prepared to execute its mission.

Recommended Content:

Coronavirus | Global Health Engagement | Global Health Engagement

Mobility Airmen conduct historic first aeromedical evacuation mission using Transport Isolation System

Article
5/4/2020
Image of three people exiting an aircraft

The TIS is an infectious disease containment unit designed to minimize risk to aircrew, medical attendants, and the airframe.

Recommended Content:

Coronavirus | Global Health Engagement | Global Health Engagement

CDC maintains childhood immunization guidelines during COVID-19

Article
5/1/2020
A child receives a vaccine during a visit to the clinic.

What you need to know about getting your child vaccinated

Recommended Content:

Coronavirus | Immunization Healthcare | Vaccine-Preventable Diseases

Immunization Tool Kit 9th Edition

Publication
4/30/2020

A practical reference that facilitates and enhances the global delivery of quality immunization healthcare to Department of Defense (DoD) beneficiaries and employees. The Defense Health Agency Immunization Healthcare Division (DHA-IHD) publishes the Immunization Tool Kit based on national recommendations, evidenced-based, peer-reviewed published medical literature, and clinical practice guidelines.

Recommended Content:

Immunization Healthcare

Amid COVID-19, seasonal influenza still a threat to force readiness

Article
4/29/2020
Hospital Corpsman administers a flu shot to a navy officer.

New Southern Hemisphere flu vaccine available May 2020

Recommended Content:

Coronavirus | Influenza Summary and Reports | Immunization Healthcare | Vaccine-Preventable Diseases | Influenza, Southern Hemisphere

A look into the future: Embedded Health Engagement Teams

Article
4/22/2020
Female soldier teaching a class

The exercise promotes bilateral cooperation by providing opportunities for U.S. and partner nation military engineers, medical personnel and support staff to work and train side by side.

Recommended Content:

Global Health Engagement | Global Health Engagement

DHA IPM 20-002: Southern Hemisphere Influenza Vaccination Program

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), establishes the Defense Health Agency’s (DHA) procedures to implement instructions, assign responsibilities, and prescribe procedures for the Southern Hemisphere Influenza Vaccination Program. All Active Duty, Selected Reserve, and National Guard members receive an annual influenza vaccination. Personnel who are traveling to, conducting a permanent change of station to, or are located in the Southern Hemisphere will receive the Southern Hemisphere influenza vaccine or obtain an exemption (e.g., medical or administrative) in accordance with guidance in paragraph 6.a. of Attachment 2. Military personnel residing in the Southern Hemisphere who have received the Southern Hemisphere influenza vaccine in accordance with Appendix 1, meet the annual influenza immunization requirement.

Coronavirus: What you need to know

Article
3/6/2020
A Guardsmen with the 341st Military Intelligence Battalion conducts translation work on a safety message regarding the best practices for avoiding the novel coronavirus for the Washington Department of Health on Feb. 9, 2020 at the Information Operations Readiness Center, Joint Base Lewis-McChord, Wash. (Courtesy Photo)

Although news stories and images contain many reports of people wearing surgical masks to ward off the virus, that's not recommended

Recommended Content:

Global Health Engagement | Public Health | Coronavirus | Coronavirus

General Best Practice Guidelines for Immunization

Publication
2/21/2020

The Centers for Disease Control and Prevention (CDC) recommends routine vaccination to prevent 17 vaccine-preventable diseases that occur in infants, children, adolescents, or adults. This report provides information for clinicians and other health care providers about concerns that commonly arise when vaccinating persons of various ages.

Recommended Content:

Immunization Healthcare | Vaccine Recommendations | Continuous Quality Immunization Improvement Process (CQIIP) and Virtual Continuous Quality Immunization Improvement Process (VCQIIP)
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 12

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.